Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
Go back to Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma| BANCO SANTANDER S.A. (NYSE: SAN) | Delayed: 12.79 +0.23 (1.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.56 | 52 Week High | $5.58 | |||
| Open | $12.61 | 52 Week Low | $3.60 | |||
| Day High | $12.81 | P/E | N/A | |||
| Day Low | $12.53 | EPS | $0.00 | |||
| Volume | 4,837,047 | |||||
| SANOFI (NASDAQ: SNY) | Delayed: 44.28 +0.17 (0.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.11 | 52 Week High | $44.76 | |||
| Open | $44.11 | 52 Week Low | $36.81 | |||
| Day High | $44.51 | P/E | N/A | |||
| Day Low | $44.02 | EPS | $0.00 | |||
| Volume | 1,135,590 | |||||
